Elocon: Advanced Topical Corticosteroid for Effective Dermatitis Relief
Elocon
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | 46.80 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 2 | 35.10 $ | 93.60 $ 70.20 $ (25%) | 🛒 Add to cart |
| 3 | 31.20 $ | 140.40 $ 93.60 $ (33%) | 🛒 Add to cart |
| 4 | 29.25 $ | 187.20 $ 117.00 $ (37%) | 🛒 Add to cart |
| 5 | 28.08 $ | 234.00 $ 140.40 $ (40%) | 🛒 Add to cart |
| 6 | 27.30 $ | 280.80 $ 163.80 $ (42%) | 🛒 Add to cart |
| 7 | 26.74 $ | 327.60 $ 187.20 $ (43%) | 🛒 Add to cart |
| 8 | 24.86 $ | 374.40 $ 198.90 $ (47%) | 🛒 Add to cart |
| 9 | 23.40 $ | 421.20 $ 210.60 $ (50%) | 🛒 Add to cart |
| 10 | 22.23 $
Best per bottle | 468.00 $ 222.30 $ (52%) | 🛒 Add to cart |
Elocon (mometasone furoate) is a high-potency topical corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is formulated to deliver targeted anti-inflammatory, antipruritic, and vasoconstrictive actions with a favorable efficacy and safety profile when used as directed. This medication is available in multiple formulations, including ointment, cream, and lotion, to suit various dermatological conditions and patient preferences. Healthcare providers prescribe Elocon for its demonstrated ability to reduce erythema, edema, and itching associated with a range of dermatologic conditions.
Features
- Contains mometasone furoate, a potent synthetic corticosteroid
- Available in 0.1% strength across ointment, cream, and lotion formulations
- Enhanced epidermal penetration due to optimized vehicle design
- Occlusive properties in ointment form for severe or lichenified conditions
- Non-comedogenic and hypoallergenic cream base suitable for facial or intertriginous areas
- Alcohol-free lotion formulation for scalp application and hairy regions
- Stabilized chemical composition ensuring consistent potency throughout shelf life
Benefits
- Rapid reduction of inflammation, erythema, and pruritus within days of initiation
- High efficacy rates in managing moderate to severe plaque psoriasis and atopic dermatitis
- Minimal systemic absorption due to selective glucocorticoid receptor affinity
- Flexible formulation options allow for tailored treatment based on lesion type and location
- Once-daily application frequency supports patient adherence to treatment regimen
- Well-tolerated with low incidence of skin atrophy when used appropriately
Common use
Elocon is primarily prescribed for the short-term treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Common indications include atopic dermatitis (eczema), psoriasis (excluding widespread plaque psoriasis), seborrheic dermatitis, and contact dermatitis. It may also be used off-label for lichen planus, discoid lupus erythematosus, and other immune-mediated dermatological conditions under specialist supervision. The medication is typically reserved for cases where medium-potency corticosteroids have proven insufficient.
Dosage and direction
Apply a thin film of Elocon to the affected area once daily. The amount needed depends on the severity and extent of the condition, but generally, fingertip units (FTUs) provide accurate dosing guidance. For adults: one FTU (approximately 0.5g) covers an area twice the size of the flat of an adult hand with fingers together. Gently massage into the skin until no longer visible. Treatment should not exceed two weeks for most dermatoses, though your physician may adjust duration based on response. Do not use under occlusive dressings unless specifically directed by a healthcare provider. Wash hands after application unless treating hands.
Precautions
Use Elocon exactly as prescribed; overuse can lead to systemic absorption and adverse effects. Avoid application to the face, groin, or axillae unless specifically directed. Discontinue if irritation develops. Do not use in patients with circulatory disorders. Monitor for signs of skin atrophy, telangiectasia, or hypopigmentation with prolonged use. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome. Use during pregnancy only if potential benefit justifies potential risk to fetus. Not for ophthalmic use.
Contraindications
Hypersensitivity to mometasone furoate or any component of the formulation. Contraindicated in patients with viral skin infections (e.g., herpes simplex, varicella), fungal infections, or bacterial skin infections without appropriate antimicrobial therapy. Should not be used on rosacea, perioral dermatitis, or acne vulgaris. Avoid use in patients with tuberculosis of the skin. Not recommended for use under occlusive dressings in children.
Possible side effect
Most common: burning, itching, irritation, and dryness at application site. Less frequent: folliculitis, hypertrichosis, acneiform eruptions, and hypopigmentation. With prolonged use or excessive application: skin atrophy, striae, telangiectasia, and miliaria. Rare systemic effects may include HPA axis suppression, glaucoma, cataract formation, and hyperglycemia. Pediatric patients may experience growth suppression with long-term use. Discontinue and consult healthcare provider if severe reactions occur.
Drug interaction
No specific drug interactions have been formally studied with topical mometasone. However, concomitant use with other topical corticosteroids may increase systemic absorption and potential for adverse effects. Use with other potentially hepatotoxic drugs may require monitoring. No known interactions with systemic medications when used topically as directed, though caution is advised in patients taking drugs that affect cortisol levels or immune response.
Missed dose
Apply as soon as remembered if within a few hours of scheduled time. If near the time of the next dose, skip the missed dose and resume regular schedule. Do not apply extra medication to compensate for missed dose. Maintain consistent once-daily application pattern for optimal therapeutic effect.
Overdose
Topical overdose may produce systemic effects including hypercorticism and adrenal suppression. Symptoms may include weight gain, rounding of the face, hypertension, and hyperglycemia. Acute overdose is unlikely with appropriate use. If ingested orally, seek immediate medical attention. Treatment involves symptomatic and supportive care. There is no specific antidote for corticosteroid overdose.
Storage
Store at room temperature (20-25°C/68-77°F). Keep tube tightly closed when not in use. Protect from freezing and excessive heat. Do not store in bathroom where moisture could affect stability. Keep all medications out of reach of children and pets. Discard any medication that has changed color or consistency. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare professional before starting any new medication. The prescribing physician should be aware of the patient’s complete medical history and current medications. Proper diagnosis and supervision are essential for safe and effective use of this medication.
Reviews
Clinical studies demonstrate Elocon achieves complete clearance or excellent improvement in 70-85% of patients with moderate to severe atopic dermatitis within 3 weeks. Dermatologists consistently rate it among the most effective Class 3 topical corticosteroids available. Patients report significant improvement in quality of life measures related to pruritus and sleep disturbance. The once-daily dosing regimen receives high satisfaction scores for convenience compared to twice-daily alternatives. Long-term safety data support its use for intermittent therapy in chronic conditions.